Skip to content

Prospective study of rituximab combined with low-dose hormone in the treatment of idiopathic membranous nephropathy

Prospective study of rituximab combined with low-dose hormone in the treatment of idiopathic membranous nephropathy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000040799
Enrollment
Unknown
Registered
2020-12-10
Start date
2020-05-20
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic membranous nephropathy

Interventions

Sponsors

The First Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Renal biopsy showed that the number of glomeruli was more than 10, and the pathological diagnosis was membranous nephropathy; 3. Baseline 24-hour urine protein quantity >= 3.5G, EGFR (CKD-EPI formula) >= 30ml / min / 1.73m2; 4. Sign informed consent.

Exclusion criteria

Exclusion criteria: 1. There are secondary factors of membranous nephropathy, such as systemic autoimmune disease, infection, tumor and so on; 2. There are contraindications of rituximab use, such as neutrophil < 1.5 * 10^9 / L, platelet < 75 * 10^9 / L, active infection, etc.; 3. Diagnosed as type 1 or type 2 diabetes.

Design outcomes

Primary

MeasureTime frame
24 hours urinary protein quantitative >= 3.5G and serum albumin > 35g / L;

Secondary

MeasureTime frame
24-hour proteinuria 0.3g-3.5g or at least 50% lower than baseline) or recurrence (progression of proteinuria after complete or partial remission, 24-hour proteinuria >= 3.5G);

Countries

China

Contacts

Public ContactQinghua Liu

The First Affiliated Hospital, Sun Yat-Sen University

fylqh1234@126.com+86 13719157606

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026